MT1


100 pM - 100 nM
Probe Information
In vitro validation
In ExpresSProfile (CEREP) MT1 showed negligible activity for over 50 ligand receptors, ion channels and transport proteins. Partial inhibition of the NK2 receptor was observed. Shown is %specific control bound radioligand when incubated with 1 uM MT1: Assay, [control ligand]: %specific bound control; VPAC1 (VIP1), [VIP]: 123.3; Y2, [NPY]: 117.05; Y1, [NPY]: 115; CB1, [CP 55940]: 112.95; CCR1, [MIP-1a]: 108.65; D2S, [(+)butaclamol]: 108.15; GAL2, [galanin]: 107.8; B2, [NPC 567]: 106.55; D1, [SCH 23390]: 105.95; 5-HT transporter, [imipramine]: 104.2; α1 (non-selective), [prazosin]: 102.95; 5-HT6, [serotonin]: 102.05; GABA (non-selective), [GABA]: 101.65; sst (non-selective), [somatostatin-14]: 101.45; α2 (non-selective), [yohimbine]: 101.35; µ (MOP), [DAMGO]: 100.5; CXCR2 (IL-8B), [IL-8]: 100.35; KV channel, [a-dendrotoxin]: 100.1; 5-HT1A, [8-OH-DPAT]: 99; BZD, [diazepam]: 97.3; MC4, [NDP-a-MSH]: 96.7; M2, [methoctramine]: 96.4; β1, [atenolol]: 96.25; Ca2+ channel (L, verapamil site) (phenylalkylamine), [D 600]: 96; κ (KOP), [U 50488]: 95.4; 5-HT3, [MDL 72222]: 94.65; NOP (ORL1), [nociceptin]: 94.35; 5-HT5a, [serotonin]: 94.2; 5-HT7, [serotonin]: 93.8; A2A, [NECA]: 93.8; NTS1 (NT1), [neurotensin]: 93.4; EP4, [PGE2]: 92.9; norepinephrine transporter, [protriptyline]: 92.9; 5-HT2A, [ketanserin]: 92.55; M1, [pirenzepine]: 92.25; SKCa channel, [apamin]: 92.1; V1a, [[d(CH2)51,Tyr(Me)2]-AVP]: 92.05; Na+ channel (site 2), [veratridine]: 91.85; β2, [ICI 118551]: 91.65; Cl- channel (GABA-gated), [picrotoxinin]: 90.5; ETA, [endothelin-1]: 90.5; 5-HT1B, [serotonin]: 90.45; dopamine transporter, [BTCP]: 89.85; M3, [4-DAMP]: 89.65; AT1, [saralasin]: 88; NK3, [SB 222200]: 87.6; 5-HT2B, [(±)DOI]: 87.45; MT1 (ML1A), [melatonin]: 86.8; H1, [pyrilamine]: 86.6; CCK1 (CCKA), [CCK-8s]: 82.95; δ2 (DOP), [DPDPE]: 81.05; A1, [DPCPX]: 79.05; H2, [cimetidine]: 77.55; A3, [IB-MECA]: 73.7; NK2, [[Nleu10]-NKA (4-10)]: 24.25;